Vera Therapeutics (VERA) Net Cash Flow (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Net Cash Flow data on file, last reported at -$240.4 million in Q1 2026.

• Quarterly Net Cash Flow fell 540.04% year-over-year to -$240.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.3 million (up 522.84% YoY) and the FY2025 annual result came in at $262.1 million, up 458.03% from the prior year.
• Net Cash Flow retreated to -$240.4 million in Q1 2026, from $297.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $297.0 million in Q4 2025 to a low of -$240.4 million in Q1 2026.
• A 5-year average of $2.0 million and a median of $2.2 million in 2024 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow soared 867.22% — and 2026, when it sank 540.04%.
• Tracing VERA's Net Cash Flow over 5 years: stood at $13.0 million in 2022, then soared by 40.48% to $18.2 million in 2023, then surged by 258.5% to $65.4 million in 2024, then surged by 354.12% to $297.0 million in 2025, then plunged by 180.95% to -$240.4 million in 2026.
• The last three Net Cash Flow figures came in at -$240.4 million (Q1 2026), $297.0 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.